RVVTF Revive Therapeutics Ltd

Revive Therapeutics Ltd., a life sciences company, focuses on the research and development of therapeutics for rare disorders and infectious diseases. The company offers novel cannabinoid-centric treatments for liver diseases, inflammatory diseases, and skin disorders. It is developing Bucillamine, which is in Phase 3 clinical study for the treatment of infectious diseases, including influenza and coronavirus disease; Psilocybin that is in Phase 1 clinical study for treating methamphetamine use disorder; Psilocybin oral formulations for the treatment of depression, anxiety, etc.; and cannabidiol for treating autoimmune hepatitis and ischemia and reperfusion injury from organ transplantation. Revive Therapeutics Ltd. has a research collaboration agreement with PharmaTher Inc. for the development of psilocybin in the treatment of cancer and the discovery of other uses of undisclosed psychedelic compounds; and with North Carolina State University for the development of a novel biosynthetic version of psilocybin based on a natural biosynthesis enzymatic platform. The company was incorporated in 2012 and is headquartered in Toronto, Canada.

This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.

$0.38    Pink
As of 06/14/2021     OTCMarkets

Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Index country:  Canada
Country of incorporation:  
IPO date:  11/30/2018
Outstanding shares:  308,417,884
Average volume:  0
Market cap:   $117,846,473
Current dividend yield:  0.00%
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   0.00
PS ratio:   0.00
Return on equity:   0.00%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy